The Scientist

» pharmaceuticals

Most Recent

image: Bayer Enters CRISPR Field

Bayer Enters CRISPR Field

By | December 22, 2015

The pharmaceutical company will spend $335 million on a new venture with biotech startup CRISPR Therapeutics.

0 Comments

image: First Dengue Vax Approved

First Dengue Vax Approved

By | December 11, 2015

Mexico’s health ministry has OKed the vaccine for people between nine and 45 years old.

0 Comments

image: Daraprim Discounts Offered

Daraprim Discounts Offered

By | November 26, 2015

Turing Pharmaceuticals will soon offer discounts to hospitals for its toxoplasmosis-fighting drug, the company announced, but some say the proposed price reductions are not enough.

0 Comments

image: Pfizer and Allergan to Merge

Pfizer and Allergan to Merge

By | November 23, 2015

The two drugmakers will join forces in a $160 billion deal—if it’s given the regulatory green light.

0 Comments

image: Daraprim Alternative

Daraprim Alternative

By | October 22, 2015

A specialty pharmaceuticals company announces plans to produce a toxoplasmosis drug containing the same active ingredient as the pill at the center of an ongoing drug-pricing controversy.

1 Comment

image: Teva Buys Mexican Pharma Firm

Teva Buys Mexican Pharma Firm

By | October 5, 2015

The Israeli drugmaker is purchasing the pharmaceutical company Rimsa for $2.3 billion.

0 Comments

image: Biotech Stocks Take a Hit

Biotech Stocks Take a Hit

By | September 30, 2015

Some say the biotech bubble has burst over concerns that drug prices are too high—and may soon be regulated.

1 Comment

image: Drug Pricing Incites Outrage

Drug Pricing Incites Outrage

By | September 22, 2015

Will public disgust over dramatic hikes in the cost of medications change industry practices?

0 Comments

image: TS Live: Pharma Feast

TS Live: Pharma Feast

By | August 26, 2015

A sampling of the biggest acquisitions reshaping the life sciences industry in 2015

0 Comments

image: Novartis Buys Rights to GSK MS Drug for $1 Billion

Novartis Buys Rights to GSK MS Drug for $1 Billion

By | August 24, 2015

The multiple sclerosis treatment has yet to be tested in Phase 3 clinical trials.

0 Comments

Popular Now

  1. Running on Empty
    Features Running on Empty

    Regularly taking breaks from eating—for hours or days—can trigger changes both expected, such as in metabolic dynamics and inflammation, and surprising, as in immune system function and cancer progression.

  2. Athletes’ Microbiomes Differ from Nonathletes
  3. Mutation Linked to Longer Life Span in Men
  4. Gut Feeling
    Daily News Gut Feeling

    Sensory cells of the mouse intestine let the brain know if certain compounds are present by speaking directly to gut neurons via serotonin.

AAAS